PDF(Pubmed)
Abstract：
UNASSIGNED: HER2-low expression breast cancer (BC) accounts for approximately 45%-55% of all BC cases. The purpose of this study was to investigate the prognostic difference between patients with HER2-low expression and HER2-zero BC.
UNASSIGNED: An electronic search of Pubmed, Embase, Cochrane Library, and Web of Science databases was performed to screen studies that included prognostic comparisons between HER2-zero and HER2-low expression groups. A total of 14 studies involving 52106 patients were included.
UNASSIGNED: Our results indicated that HER2-low expression was associated with a significant benefit in OS among all patients with early BC (HR, 0.83; 95% CI, 0.78-0.88), patients with hormone-receptor positive BC (HR, 0.83; 95% CI, 0.77-0.89), and patients with TNBC (HR, 0.78; 95% CI, 0.70-0.87). HER2-low expression was associated with a significant benefit in DFS among all patients (HR, 0.81; 95% CI, 0.71-0.93), patients with hormone receptor-positive BC (HR, 0.81; 95% CI, 0.72-0.90), but no significant difference in DFS was found in patients with TNBC (HR, 0.87; 95% CI, 0.65-1.17). HER2-low expression was associated with a significant benefit in RFS among all patients (HR, 0.90; 95% CI, 0.85-0.95), patients with hormone receptor-positive BC (HR, 0.90; 95% CI, 0.84-0.96), but no significant difference in RFS was found in patients with TNBC (HR, 0.80; 95% CI, 0.55-1.16).
UNASSIGNED: Among patients with early-stage BC, patients with HER2-low expression BC had better OS in the overall population, hormone receptor-positive and TNBC subgroups. Besides, favorable DFS and RFS were observed in both the overall population and hormone receptor-positive subgroup.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/, identifier (CRD 42022349458).
UNASSIGNED: An electronic search of Pubmed, Embase, Cochrane Library, and Web of Science databases was performed to screen studies that included prognostic comparisons between HER2-zero and HER2-low expression groups. A total of 14 studies involving 52106 patients were included.
UNASSIGNED: Our results indicated that HER2-low expression was associated with a significant benefit in OS among all patients with early BC (HR, 0.83; 95% CI, 0.78-0.88), patients with hormone-receptor positive BC (HR, 0.83; 95% CI, 0.77-0.89), and patients with TNBC (HR, 0.78; 95% CI, 0.70-0.87). HER2-low expression was associated with a significant benefit in DFS among all patients (HR, 0.81; 95% CI, 0.71-0.93), patients with hormone receptor-positive BC (HR, 0.81; 95% CI, 0.72-0.90), but no significant difference in DFS was found in patients with TNBC (HR, 0.87; 95% CI, 0.65-1.17). HER2-low expression was associated with a significant benefit in RFS among all patients (HR, 0.90; 95% CI, 0.85-0.95), patients with hormone receptor-positive BC (HR, 0.90; 95% CI, 0.84-0.96), but no significant difference in RFS was found in patients with TNBC (HR, 0.80; 95% CI, 0.55-1.16).
UNASSIGNED: Among patients with early-stage BC, patients with HER2-low expression BC had better OS in the overall population, hormone receptor-positive and TNBC subgroups. Besides, favorable DFS and RFS were observed in both the overall population and hormone receptor-positive subgroup.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/, identifier (CRD 42022349458).
摘要：
未经证实：HER2低表达乳腺癌（BC）约占所有BC病例的45％-55％。目的探讨HER2-低表达患者与HER2-零BC患者的预后差异。
未经授权：对Pubmed的电子搜索，Embase,科克伦图书馆,和WebofScience数据库用于筛选研究,这些研究包括HER2-0和HER2低表达组之间的预后比较.共纳入14项研究，涉及52106名患者。
UNASSIGNED：我们的结果表明，在所有早期BC患者中，HER2低表达与OS的显着益处相关（HR，0.83；95%CI，0.78-0.88），激素受体阳性BC患者(HR，0.83；95%CI，0.77-0.89），和TNBC患者(HR，0.78；95%CI，0.70-0.87）。在所有患者中，HER2低表达与DFS的显着获益相关（HR，0.81；95%CI，0.71-0.93），激素受体阳性BC患者(HR，0.81；95%CI，0.72-0.90），但在TNBC患者中DFS没有发现显著差异(HR，0.87；95%CI，0.65-1.17）。在所有患者中，HER2低表达与RFS的显着获益相关（HR，0.90；95%CI，0.85-0.95），激素受体阳性BC患者(HR，0.90；95%CI，0.84-0.96），但TNBC患者的RFS无显著差异(HR，0.80；95%CI，0.55-1.16）。
未经证实：在早期BC患者中，HER2低表达BC患者在总体人群中有较好的OS,激素受体阳性和TNBC亚组。此外,在总体人群和激素受体阳性亚组均观察到有利的DFS和RFS.
UNASSIGNED：https://www。crd.约克。AC.英国/PROSPERO/,标识符(CRD42022349458)。
未经授权：对Pubmed的电子搜索，
UNASSIGNED：我们的结果表明，在所有早期BC患者中，HER2低表达与OS的显着益处相关（HR，
未经证实：在早期BC患者中，
UNASSIGNED：https://www。
